^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    L-pampo

    Associations

    News

    Trials
    Company:
    CHA Vaccine Institute
    Drug class:
    TLR3 agonist, TLR1 agonist, TLR2 agonist
    Related drugs:
    Associations

    News

    Trials
    over2years
    Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. (PubMed, J Immunother Cancer)
    Our study demonstrated that intratumoral LP treatment improves the innate and adaptive antitumor immunity within the TME and enhances the efficacy of αPD-1 and αCTLA-4 immune checkpoint blockade.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule)
    |
    L-pampo